Hyperion Therapeutics Elects David W. Gryska to Board of Directors

Hyperion Therapeutics Elects David W. Gryska to Board of Directors


SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 9, 2010 - Hyperion Therapeutics, Inc., a privately held pharmaceutical company, today announced that David W. Gryska has been elected to the Company's Board of Directors. Mr. Gryska will also serve on the Audit Committee.

"We are pleased to welcome Dave to our Board of Directors," said Donald J. Santel, Chief Executive Officer of Hyperion Therapeutics, Inc. "Dave brings a wealth of financial and operating experience in the biopharmaceutical industry, and a track record of success at both Scios and Celgene, which will add direct and immediate value to the Hyperion team."

"Hyperion is going through a very exciting evolution as it prepares to request U.S. Food and Drug Administration approval of glycerol phenylbutyrate, an investigational drug for the treatment of urea cycle disorders," said Mr. Gryska. "I look forward to working with the Hyperion Board and experienced senior management team as they execute the clinical, regulatory and commercial activities necessary to fully capitalize on this opportunity."

Most recently, Mr. Gryska served as Senior Vice President and Chief Financial Officer at Celgene, Inc. (CELG) where he was responsible for all finance functions, corporate communications, and strategic planning. Prior to Celgene, he served as Senior Vice President and Chief Financial Officer at Scios, Inc., where he led the transaction effort for the successful sale of the company to Johnson & Johnson for $2.5 billion in February 2003. Earlier in his career, Mr. Gryska served as a partner at Ernst & Young, with an emphasis on biotechnology and healthcare companies. He has served on the Board of Directors of various private and public healthcare companies and currently serves as a member of the Board of Directors of Seattle Genetics (SGEN).

About Hyperion Therapeutics

Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology. The Company is currently developing glycerol phenylbutyrate (HPN-100) for urea cycle disorders (UCD) and hepatic encephalopathy. Hyperion acquired development rights for glycerol phenylbutyrate from Ucyclyd Pharma, Inc. (a subsidiary of Medicis Pharmaceutical Corporation) in 2007 and has the right to acquire worldwide commercialization rights if the product is FDA-approved for UCD. Hyperion is headquartered in South San Francisco, CA. For additional information, visit www.hyperiontx.com.

 

Contact: Hyperion Therapeutics, Inc.
Christine Nash, 650-745-7844

 

 

Suggested Articles

A phase 1/2b test showed Roche's antibody mosunetuzumab can trigger durable responses in a significant minority of hard-to-treat NHL patients.

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.